Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Carrie M Hersh - , Lou Ruvo Center for Brain Health (LRCBH) (Author)
  • Menglan Pang - , Biogen (Author)
  • Deborah M Miller - , Cleveland Clinic Ohio (Author)
  • Marisa P McGinley - , Cleveland Clinic Ohio (Author)
  • Megan Hyland - , University of Rochester Medical Center (Author)
  • Tjalf Ziemssen - , Department of Neurology, University Hospital Carl Gustav Carus Dresden (Author)
  • Robin L Avila - , Biogen (Author)

Abstract

Aim: To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. Methods: Patients enrolled in the MS PATHS network who initiated treatment with either natalizumab or ocrelizumab rated the Neuro-QoL domains of physical function, symptoms, emotional health, cognitive function and social ability. Results: Time to clinically meaningful improvement was significantly shorter with natalizumab versus ocrelizumab for cognitive function (event time ratio [95% CI]: 0.37 [0.24-0.57]; p < 0.001), sleep disturbance (0.45 [0.28-0.72]; p = 0.001), social role participation (0.37 [0.21-0.66]; p = 0.001) and social role satisfaction (0.5 [0.31-0.8]; p = 0.004). Conclusion: Natalizumab had shorter time to clinically meaningful improvement in cognitive, sleep, and social role Neuro-QoL domains versus ocrelizumab.

Details

Original languageEnglish
Pages (from-to)21-33
Number of pages13
JournalNeurodegenerative disease management
Volume14
Issue number2
Publication statusE-pub ahead of print - 16 Apr 2024
Peer-reviewedYes

External IDs

unpaywall 10.2217/nmt-2023-0047
Mendeley cf97f4dd-3211-320f-8b09-685609515ab3
Scopus 85193411372
ORCID /0000-0001-8799-8202/work/171553660

Keywords